1. Inicio
  2. Publicaciones
  3. Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study

Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Ethier, JL
  • Ocana, A
  • Lescure, AR
  • Ruiz, A
  • Alba, E
  • Calvo, L
  • Ruiz-Borrego, M
  • Rodriguez, CA
  • Crespo, C
  • Ramos, M
  • Marco, JG
  • Lluch, A
  • Alvarez, I
  • Casas, M
  • Sanchez-Arago, M
  • Carrasco, E
  • Caballero, R
  • Amir, E
  • Martin, M

Grupos

Abstract

Background: Retrospective data suggest better outcomes for patients with double hormonal receptor (oestrogen [ER] and progesterone receptor [PgR])-positive (dHR+) early breast cancer, compared with single hormonal receptor positive, sHR+, (ER+/PgR- or ER -/PgR+) disease. Here, we evaluate the classification according to intrinsic subtypes and clinical outcomes of sHR + versus dHR + in HER2-negative breast cancer patients enrolled in GEICAM/9906 study (NCT00129922). Methods: Archival tumours were retrieved retrospectively for the analysis of ER, PgR and HER2 status and classified into intrinsic subtypes using the PAM50 gene expression assay. Disease-free survival (DFS) and overall survival (OS) were explored using a Cox proportional hazard analysis. Results: Data on intrinsic subtypes were available in 571 (50%) patients with ER + and/or PR+, and HER2-negative primary tumours. The incidence of luminal A and luminal B subtypes were 52%/36% in dHR + tumours (ER+/PgR+), and 15%/58% in ER+/PgR-tumours. ER/PgR+ tumours were mainly luminal A (52%). Compared with ER+/PgR+ patients, DFS was similar in ER- /PgR+ (hazard ratio [HR] 1.15, 95% confidence interval [CI] 0.57-2.34, p = 0.70) but worse in ER+/PgR patients (HR 1.60, 95% CI 1.12-2.28, p < 0.01). Similar results were observed for OS (HR 1.50, p = 0.30 and HR 1.86, p < 0.01, respectively). Conclusions: The ER+/PgR group is characterised by higher proliferation and worse outcomes. In spite of the ER-/PgR+ subgroup resembles ER+/PgR+ disease in terms of molecular subtypes and outcomes, the small number of patients in this subgroup prevents from drawing any conclusions. (C) 2018 Elsevier Ltd. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
0959-8049, 1879-0852

EUROPEAN JOURNAL OF CANCER  ELSEVIER SCI LTD

Tipo:
Article
Páginas:
199-205
PubMed:
29573665
Factor de Impacto:
3,839 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 15

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Breast cancer; Single receptor positive; Hormone receptor positive; Intrinsic subtypes; PAM50

Campos de Estudio

Cita

Compartir